

# Joseph A Sparano

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6717134/publications.pdf>

Version: 2024-02-01

290  
papers

21,262  
citations

14614

66  
h-index

10708

138  
g-index

295  
all docs

295  
docs citations

295  
times ranked

23099  
citing authors

#	ARTICLE	IF	CITATIONS
1	Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. <i>New England Journal of Medicine</i> , 2018, 379, 111-121.	13.9	1,558
2	Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. <i>New England Journal of Medicine</i> , 2015, 373, 2005-2014.	13.9	1,146
3	Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199. <i>Journal of Clinical Oncology</i> , 2014, 32, 2959-2966.	0.8	1,080
4	Weekly Paclitaxel in the Adjuvant Treatment of Breast Cancer. <i>New England Journal of Medicine</i> , 2008, 358, 1663-1671.	13.9	855
5	Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. <i>Lancet Oncology</i> , The, 2018, 19, 27-39.	5.1	717
6	Proposal for Standardized Definitions for Efficacy End Points in Adjuvant Breast Cancer Trials: The STEEP System. <i>Journal of Clinical Oncology</i> , 2007, 25, 2127-2132.	0.8	709
7	Development of the 21-Gene Assay and Its Application in Clinical Practice and Clinical Trials. <i>Journal of Clinical Oncology</i> , 2008, 26, 721-728.	0.8	536
8	Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors. <i>Advances in Anatomic Pathology</i> , 2017, 24, 211-235.	2.4	530
9	Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research. <i>Advances in Anatomic Pathology</i> , 2017, 24, 235-251.	2.4	469
10	A Multigene Expression Assay to Predict Local Recurrence Risk for Ductal Carcinoma In Situ of the Breast. <i>Journal of the National Cancer Institute</i> , 2013, 105, 701-710.	3.0	442
11	Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. <i>Blood</i> , 2005, 106, 1538-1543.	0.6	390
12	Neoadjuvant chemotherapy induces breast cancer metastasis through a TMEM-mediated mechanism. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	370
13	Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer. <i>New England Journal of Medicine</i> , 2019, 380, 2395-2405.	13.9	349
14	Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 115-126.	5.1	333
15	Randomized Controlled Trial of Yoga Among a Multiethnic Sample of Breast Cancer Patients: Effects on Quality of Life. <i>Journal of Clinical Oncology</i> , 2007, 25, 4387-4395.	0.8	324
16	Prognostic Utility of the 21-Gene Assay in Hormone Receptor-Positive Operable Breast Cancer Compared With Classical Clinicopathologic Features. <i>Journal of Clinical Oncology</i> , 2008, 26, 4063-4071.	0.8	312
17	Seroconversion rates following COVID-19 vaccination among patients with cancer. <i>Cancer Cell</i> , 2021, 39, 1081-1090.e2.	7.7	285
18	Current Landscape of Immunotherapy in Breast Cancer. <i>JAMA Oncology</i> , 2019, 5, 1205.	3.4	260

#	ARTICLE	IF	CITATIONS
19	Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37â€²298 women with early breast cancer in 26 randomised trials. <i>Lancet, The</i> , 2019, 393, 1440-1452.	6.3	260
20	Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma. <i>Blood</i> , 2010, 115, 3008-3016.	0.6	254
21	TAILORx: Trial Assigning Individualized Options for Treatment (Rx). <i>Clinical Breast Cancer</i> , 2006, 7, 347-350.	1.1	242
22	Progress in adjuvant chemotherapy for breast cancer: an overview. <i>BMC Medicine</i> , 2015, 13, 195.	2.3	241
23	Surgical Excision Without Radiation for Ductal Carcinoma in Situ of the Breast: 12-Year Results From the ECOG-ACRIN E5194 Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 3938-3944.	0.8	223
24	Randomized Phase III Trial of Marimastat Versus Placebo in Patients With Metastatic Breast Cancer Who Have Responding or Stable Disease After First-Line Chemotherapy: Eastern Cooperative Oncology Group Trial E2196. <i>Journal of Clinical Oncology</i> , 2004, 22, 4683-4690.	0.8	218
25	Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, As First-Line Therapy in Patients With Metastatic Breast Cancer Previously Treated With Anthracycline Chemotherapy. <i>Journal of Clinical Oncology</i> , 2007, 25, 3415-3420.	0.8	217
26	Estrogen- and Progesterone-Receptor Status in ECOG 2197: Comparison of Immunohistochemistry by Local and Central Laboratories and Quantitative Reverse Transcription Polymerase Chain Reaction by Central Laboratory. <i>Journal of Clinical Oncology</i> , 2008, 26, 2473-2481.	0.8	212
27	Randomized Phase III Trial of Ixabepilone Plus Capecitabine Versus Capecitabine in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane. <i>Journal of Clinical Oncology</i> , 2010, 28, 3256-3263.	0.8	203
28	Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and <i>BRCA1</i>/<i>2</i> Mutationâ€“Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105. <i>Journal of Clinical Oncology</i> , 2015, 33, 1895-1901.	0.8	200
29	Dasatinib as a Single Agent in Triple-Negative Breast Cancer: Results of an Open-Label Phase 2 Study. <i>Clinical Cancer Research</i> , 2011, 17, 6905-6913.	3.2	183
30	Obesity at diagnosis is associated with inferior outcomes in hormone receptorâ€“positive operable breast cancer. <i>Cancer</i> , 2012, 118, 5937-5946.	2.0	174
31	Survival in patients with metastatic recurrent breast cancer after adjuvant chemotherapy. <i>Cancer</i> , 2013, 119, 1140-1148.	2.0	173
32	Long-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 2353-2360.	0.8	167
33	Treatment of Anal High-Grade Squamous Intraepithelial Lesions to Prevent Anal Cancer. <i>New England Journal of Medicine</i> , 2022, 386, 2273-2282.	13.9	164
34	Targeting insulin inhibition as a metabolic therapy in advanced cancer: A pilot safety and feasibility dietary trial in 10 patients. <i>Nutrition</i> , 2012, 28, 1028-1035.	1.1	160
35	Tumor Microenvironment of Metastasis and Risk of Distant Metastasis of Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	3.0	158
36	Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients. <i>Blood</i> , 2013, 122, 3251-3262.	0.6	156

#	ARTICLE	IF	CITATIONS
37	Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 2206-2216.	0.8	152
38	Association of Circulating Tumor Cells With Late Recurrence of Estrogen Receptorâ€“Positive Breast Cancer. <i>JAMA Oncology</i> , 2018, 4, 1700.	3.4	151
39	Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virusâ€“associated Kaposi sarcoma. <i>Cancer</i> , 2010, 116, 3969-3977.	2.0	138
40	Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptorâ€“Positive, Human Epidermal Growth Factor Receptor 2â€“Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE0102. <i>Journal of Clinical Oncology</i> , 2018, 36, 1556-1563.	0.8	134
41	If we build it they will come: targeting the immune response to breast cancer. <i>Npj Breast Cancer</i> , 2019, 5, 37.	2.3	132
42	Expression, Clinical Significance, and Receptor Identification of the Newest B7 Family Member HHLA2 Protein. <i>Clinical Cancer Research</i> , 2015, 21, 2359-2366.	3.2	125
43	Phase II Trial of Saracatinib (AZD0530), an Oral SRC-inhibitor for the Treatment of Patients with Hormone Receptor-negative Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2011, 11, 306-311.	1.1	118
44	Phase III Comparison of Tamoxifen Versus Tamoxifen Plus Ovarian Function Suppression in Premenopausal Women With Node-Negative, Hormone Receptorâ€“Positive Breast Cancer (E-3193). <i>Journal of Clinical Oncology</i> , 2011, 29, 3948-3958.	0.8	118
45	Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma. <i>Cancer</i> , 2011, 117, 336-342.	2.0	116
46	Phase II Trial of Infusional Cyclophosphamide, Doxorubicin, and Etoposide in Patients With HIV-Associated Non-Hodgkinâ€™s Lymphoma: An Eastern Cooperative Oncology Group Trial (E1494). <i>Journal of Clinical Oncology</i> , 2004, 22, 1491-1500.	0.8	114
47	Phase I Trial of Toll-Like Receptor 9 Agonist PF-3512676 with and Following Rituximab in Patients with Recurrent Indolent and Aggressive Nonâ€“Hodgkin's Lymphoma. <i>Clinical Cancer Research</i> , 2007, 13, 6168-6174.	3.2	111
48	Genome-Wide Association Studies for Taxane-Induced Peripheral Neuropathy in ECOG-5103 and ECOG-1199. <i>Clinical Cancer Research</i> , 2015, 21, 5082-5091.	3.2	106
49	Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. <i>Npj Breast Cancer</i> , 2020, 6, 17.	2.3	106
50	Conducting Molecular Epidemiological Research in the Age of HIPAA: A Multi-Institutional Case-Control Study of Breast Cancer in African-American and European-American Women. <i>Journal of Oncology</i> , 2009, 2009, 1-15.	0.6	104
51	Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy. <i>JAMA Oncology</i> , 2020, 6, 367.	3.4	100
52	Pegylated Liposomal Doxorubicin Plus Docetaxel Significantly Improves Time to Progression Without Additive Cardiotoxicity Compared With Docetaxel Monotherapy in Patients With Advanced Breast Cancer Previously Treated With Neoadjuvant-Adjuvant Anthracycline Therapy: Results From a Randomized Phase III Study. <i>Journal of Clinical Oncology</i> , 2009, 27, 4522-4529.	0.8	97
53	Concurrent Doxorubicin Plus Docetaxel Is Not More Effective Than Concurrent Doxorubicin Plus Cyclophosphamide in Operable Breast Cancer With 0 to 3 Positive Axillary Nodes: North American Breast Cancer Intergroup Trial E 2197. <i>Journal of Clinical Oncology</i> , 2008, 26, 4092-4099.	0.8	93
54	HHLA2 and TMIGD2: new immunotherapeutic targets of the B7 and CD28 families. <i>Oncolmmunology</i> , 2015, 4, e1026534.	2.1	93

#	ARTICLE	IF	CITATIONS
55	Caveolin-1 Mutations in Human Breast Cancer. <i>American Journal of Pathology</i> , 2006, 168, 1998-2013.	1.9	92
56	A Phase 2 Trial of Dasatinib in Patients with Advanced HER2-Positive and/or Hormone Receptor-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 6897-6904.	3.2	90
57	Immunophenotypic Analysis of AIDS-Related Diffuse Large B-Cell Lymphoma and Clinical Implications in Patients From AIDS Malignancies Consortium Clinical Trials 010 and 034. <i>Journal of Clinical Oncology</i> , 2009, 27, 5039-5048.	0.8	89
58	Race and Hormone Receptor-Positive Breast Cancer Outcomes in a Randomized Chemotherapy Trial. <i>Journal of the National Cancer Institute</i> , 2012, 104, 406-414.	3.0	89
59	Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline <i>BRCA1</i> or <i>BRCA2</i> -Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083. <i>Clinical Cancer Research</i> , 2017, 23, 4066-4076.	3.2	87
60	Early Local Therapy for the Primary Site in De Novo Stage IV Breast Cancer: Results of a Randomized Clinical Trial (E2108). <i>Journal of Clinical Oncology</i> , 2022, 40, 978-987.	0.8	86
61	Therapies for triple negative breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 983-998.	0.9	85
62	E2112: randomized phase iii trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer. <i>Npj Breast Cancer</i> , 2018, 4, 1.	2.3	84
63	Neuropathy Is Not Associated With Clinical Outcomes in Patients Receiving Adjuvant Taxane-Containing Therapy for Operable Breast Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 3051-3057.	0.8	83
64	Pooled analysis of AIDS malignancy consortium trials evaluating rituximab plus CHOP or infusional EPOCH chemotherapy in HIV-associated non-Hodgkin lymphoma. <i>Cancer</i> , 2012, 118, 3977-3983.	2.0	81
65	Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131. <i>Journal of Clinical Oncology</i> , 2021, 39, 2539-2551.	0.8	78
66	Phase II Trial of Doxorubicin and Docetaxel Plus Granulocyte Colony-Stimulating Factor in Metastatic Breast Cancer: Eastern Cooperative Oncology Group Study E1196. <i>Journal of Clinical Oncology</i> , 2000, 18, 2369-2377.	0.8	76
67	Genome-Wide Association Study for Anthracycline-Induced Congestive Heart Failure. <i>Clinical Cancer Research</i> , 2017, 23, 43-51.	3.2	73
68	Cetuximab Plus Chemoradiotherapy in Immunocompetent Patients With Anal Carcinoma: A Phase II Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group Trial (E3205). <i>Journal of Clinical Oncology</i> , 2017, 35, 718-726.	0.8	70
69	A Phase I-II Study of Combined Blockade of the ErbB Receptor Network with Trastuzumab and Gefitinib in Patients with HER2 (ErbB2)-Overexpressing Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2008, 14, 6277-6283.	3.2	69
70	Phase II Trial of Tipifarnib plus Neoadjuvant Doxorubicin-Cyclophosphamide in Patients with Clinical Stage IIB-IIIC Breast Cancer. <i>Clinical Cancer Research</i> , 2009, 15, 2942-2948.	3.2	69
71	Prognostic value of biologic subtype and the 21-gene recurrence score relative to local recurrence after breast conservation treatment with radiation for early stage breast carcinoma: results from the Eastern Cooperative Oncology Group E2197 study. <i>Breast Cancer Research and Treatment</i> , 2012, 134, 683-692.	1.1	69
72	Development and Validation of a Tool Integrating the 21-Gene Recurrence Score and Clinical-Pathological Features to Individualize Prognosis and Prediction of Chemotherapy Benefit in Early Breast Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 557-564.	0.8	69

#	ARTICLE	IF	CITATIONS
73	Akt Inhibitors MK-2206 and Nelfinavir Overcome mTOR Inhibitor Resistance in Diffuse Large B-cell Lymphoma. <i>Clinical Cancer Research</i> , 2012, 18, 2534-2544.	3.2	66
74	A common language in neoadjuvant breast cancer clinical trials: proposals for standard definitions and endpoints. <i>Lancet Oncology</i> , The, 2012, 13, e240-e248.	5.1	64
75	Cetuximab Plus Chemoradiotherapy for HIV-Associated Anal Carcinoma: A Phase II AIDS Malignancy Consortium Trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 727-733.	0.8	64
76	Human Immunodeficiency Virus/AIDS, Human Papillomavirus, and Anal Cancer. <i>Surgical Oncology Clinics of North America</i> , 2017, 26, 17-31.	0.6	64
77	Targeted Inhibition of Farnesyltransferase in Locally Advanced Breast Cancer: A Phase I and II Trial of Tipifarnib Plus Dose-Dense Doxorubicin and Cyclophosphamide. <i>Journal of Clinical Oncology</i> , 2006, 24, 3013-3018.	0.8	63
78	Saquinavir enhances the mucosal toxicity of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkin's lymphoma. <i>Medical Oncology and Tumor Pharmacotherapy</i> , 1998, 15, 50-57.	1.0	62
79	Race, Ethnicity, and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer in the Randomized TAILORx Trial. <i>Journal of the National Cancer Institute</i> , 2021, 113, 390-399.	3.0	62
80	Patient-Reported Cognitive Impairment Among Women With Early Breast Cancer Randomly Assigned to Endocrine Therapy Alone Versus Chemoendocrine Therapy: Results From TAILORx. <i>Journal of Clinical Oncology</i> , 2020, 38, 1875-1886.	0.8	59
81	Structure and Cancer Immunotherapy of the B7 Family Member B7x. <i>Cell Reports</i> , 2014, 9, 1089-1098.	2.9	58
82	Colonic ischemia complicating immunotherapy with interleukin-2 and interferon-alpha. <i>Cancer</i> , 1991, 68, 1538-1544.	2.0	56
83	Eribulin mesylate versus ixabepilone in patients with metastatic breast cancer: a randomized Phase II study comparing the incidence of peripheral neuropathy. <i>Breast Cancer Research and Treatment</i> , 2013, 140, 341-351.	1.1	56
84	Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: A phase II study based on surgical reassessment. <i>Gynecologic Oncology</i> , 2010, 119, 451-456.	0.6	55
85	Defining a Role and Predicting Benefit From Platinum-Based Therapy in Breast Cancer: An Evolving Story. <i>Journal of Clinical Oncology</i> , 2015, 33, 1-3.	0.8	55
86	Tumor infiltrating lymphocytes (TILs) improve prognosis in patients with triple negative breast cancer (TNBC). <i>Oncimmunology</i> , 2015, 4, e985930.	2.1	55
87	Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer. <i>Npj Breast Cancer</i> , 2019, 5, 34.	2.3	55
88	E2112: Randomized Phase III Trial of Endocrine Therapy Plus Entinostat or Placebo in Hormone Receptor-Positive Advanced Breast Cancer. A Trial of the ECOG-ACRIN Cancer Research Group. <i>Journal of Clinical Oncology</i> , 2021, 39, 3171-3181.	0.8	54
89	Chemotherapy in Patients with Anthracycline and Taxane-Pretreated Metastatic Breast Cancer: An Overview. <i>Current Breast Cancer Reports</i> , 2013, 5, 42-50.	0.5	52
90	Prognostic and Predictive Value of Tumor Vascular Endothelial Growth Factor Gene Amplification in Metastatic Breast Cancer Treated with Paclitaxel with and without Bevacizumab; Results from ECOG 2100 Trial. <i>Clinical Cancer Research</i> , 2013, 19, 1281-1289.	3.2	52

#	ARTICLE	IF	CITATIONS
91	A phase I-II study of the histone deacetylase inhibitor vorinostat plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in locally advanced breast cancer. <i>Breast Cancer Research and Treatment</i> , 2014, 146, 145-152.	1.1	52
92	Double-Blind Phase III Trial of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node-Positive and High-Risk Lymph Node-Negative Breast Cancer (E5103). <i>Journal of Clinical Oncology</i> , 2018, 36, 2621-2629.	0.8	52
93	Clinical and Translational Results of a Phase II, Randomized Trial of an Anti-IGF-1R (Cixutumumab) in Women with Breast Cancer That Progressed on Endocrine Therapy. <i>Clinical Cancer Research</i> , 2016, 22, 301-309.	3.2	51
94	A metastasis biomarker (MetaSite Breast <sub>+</sub> Score) is associated with distant recurrence in hormone receptor-positive, HER2-negative early-stage breast cancer. <i>Npj Breast Cancer</i> , 2017, 3, 42.	2.3	48
95	GRB7 is required for triple-negative breast cancer cell invasion and survival. <i>Breast Cancer Research and Treatment</i> , 2012, 133, 607-615.	1.1	46
96	Patterns of central nervous system recurrence in patients with systemic human immunodeficiency virus-associated non-Hodgkin lymphoma. <i>Cancer</i> , 1999, 86, 1840-1847.	2.0	43
97	A new prognostic score for AIDS-related lymphomas in the rituximab-era. <i>Haematologica</i> , 2014, 99, 1731-1737.	1.7	42
98	Biomarker prediction of chemotherapy-related amenorrhea in premenopausal women with breast cancer participating in E5103. <i>Breast Cancer Research and Treatment</i> , 2014, 144, 591-597.	1.1	40
99	Phase II Study of Paclitaxel Plus the Protein Kinase C Inhibitor Bryostatins-1 in Advanced Pancreatic Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2010, 33, 121-124.	0.6	40
100	Human T Cell Leukemia Virus Reactivation with Progression of Adult T-Cell Leukemia-Lymphoma. <i>PLoS ONE</i> , 2009, 4, e4420.	1.1	40
101	Phase I Trial of Escalating Doses of Paclitaxel Plus Doxorubicin and Dexrazoxane in Patients With Advanced Breast Cancer. <i>Journal of Clinical Oncology</i> , 1999, 17, 880-880.	0.8	39
102	A phase II trial of trastuzumab plus weekly ixabepilone and carboplatin in patients with HER2-positive metastatic breast cancer: an Eastern Cooperative Oncology Group Trial. <i>Breast Cancer Research and Treatment</i> , 2010, 119, 663-671.	1.1	39
103	Phase II trial of echinomycin in patients with advanced or recurrent colorectal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 1994, 34, 266-269.	1.1	38
104	Bevacizumab (Bv) in the adjuvant treatment of HER2-negative breast cancer: Final results from Eastern Cooperative Oncology Group E5103.. <i>Journal of Clinical Oncology</i> , 2014, 32, 500-500.	0.8	38
105	Ixabepilone-associated peripheral neuropathy: data from across the phase II and III clinical trials. <i>Supportive Care in Cancer</i> , 2012, 20, 2661-2668.	1.0	36
106	Charcot-Marie-Tooth gene, SBF2, associated with taxane-induced peripheral neuropathy in African Americans. <i>Oncotarget</i> , 2016, 7, 82244-82253.	0.8	35
107	Pathologic complete response (pCR) rates after neoadjuvant trastuzumab emtansine (T-DM1 [K]) + pertuzumab (P) vs docetaxel + carboplatin + trastuzumab + P (TCHP) treatment in patients with HER2-positive (HER2+) early breast cancer (EBC) (KRISTINE).. <i>Journal of Clinical Oncology</i> , 2016, 34, 500-500.	0.8	32
108	ACCO: ASCO Core Curriculum Outline. <i>Journal of Clinical Oncology</i> , 2005, 23, 2049-2077.	0.8	31

#	ARTICLE	IF	CITATIONS
109	Effects of Radiotherapy in Early-Stage, Low-Recurrence Risk, Hormone-Sensitive Breast Cancer. Journal of the National Cancer Institute, 2018, 110, 1370-1379.	3.0	31
110	The Contribution of Race to Breast Tumor Microenvironment Composition and Disease Progression. Frontiers in Oncology, 2020, 10, 1022.	1.3	31
111	Pilot study evaluating the interaction between paclitaxel and protease inhibitors in patients with human immunodeficiency virus-associated Kaposi's sarcoma: an Eastern Cooperative Oncology Group (ECOG) and AIDS Malignancy Consortium (AMC) trial. Cancer Chemotherapy and Pharmacology, 2011, 68, 827-833.	1.1	28
112	Correlation between the DCIS score and traditional clinicopathologic features in the prospectively designed E5194 clinical validation study.. Journal of Clinical Oncology, 2012, 30, 1005-1005.	0.8	28
113	High Expression of Class III $\beta$ -Tubulin Predicts Good Response to Neoadjuvant Taxane and Doxorubicin/Cyclophosphamide-Based Chemotherapy in Estrogen Receptor-Negative Breast Cancer. Clinical Breast Cancer, 2013, 13, 103-108.	1.1	27
114	Assessment of Racial Disparity in Survival Outcomes for Early Hormone Receptor-Positive Breast Cancer After Adjusting for Insurance Status and Neighborhood Deprivation. JAMA Oncology, 2022, 8, 579.	3.4	27
115	Phase II trial of pegylated liposomal doxorubicin plus docetaxel with and without trastuzumab in metastatic breast cancer: Eastern Cooperative Oncology Group Trial E3198. Breast Cancer Research and Treatment, 2010, 121, 111-120.	1.1	26
116	Clinical Studies Examining the Impact of Obesity on Breast Cancer Risk and Prognosis. Journal of Mammary Gland Biology and Neoplasia, 2013, 18, 257-266.	1.0	26
117	Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: a New York Cancer Consortium trial. Npj Breast Cancer, 2016, 2, 16037.	2.3	26
118	Phase I trial of metronomic oral vinorelbine in patients with advanced cancer. Cancer Chemotherapy and Pharmacology, 2011, 68, 1119-1124.	1.1	25
119	Taxanes. Anti-Cancer Drugs, 2014, 25, 512-521.	0.7	25
120	Phase II trial of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehydethiosemicarbazone plus gemcitabine in patients with advanced biliary tract cancer. Cancer Chemotherapy and Pharmacology, 2011, 68, 379-388.	1.1	24
121	Plasmablastic lymphoma is treatable in the HAART era. A 10 year retrospective by the AIDS Malignancy Consortium. Leukemia and Lymphoma, 2016, 57, 1731-1734.	0.6	24
122	Relationship between Topoisomerase 2A RNA Expression and Recurrence after Adjuvant Chemotherapy for Breast Cancer. Clinical Cancer Research, 2009, 15, 7693-7700.	3.2	23
123	Impact of Genetic Ancestry on Outcomes in ECOG-ACRIN-5103. JCO Precision Oncology, 2017, 2017, 1-9.	1.5	23
124	Association of Magnetic Resonance Imaging and a 12-Gene Expression Assay With Breast Ductal Carcinoma In Situ Treatment. JAMA Oncology, 2019, 5, 1036.	3.4	23
125	Clinical Application of Gene Expression Profiling in Breast Cancer. Surgical Oncology Clinics of North America, 2010, 19, 581-606.	0.6	22
126	Ixabepilone plus capecitabine in metastatic breast cancer patients with reduced performance status previously treated with anthracyclines and taxanes: a pooled analysis by performance status of efficacy and safety data from 2 phase III studies. Breast Cancer Research and Treatment, 2011, 125, 755-765.	1.1	22

#	ARTICLE	IF	CITATIONS
127	AIDS and non-AIDS diffuse large B-cell lymphomas express different antigen profiles. <i>Modern Pathology</i> , 2006, 19, 438-446.	2.9	21
128	Randomized Phase II Study of Ramucirumab or Icrucumab in Combination with Capecitabine in Patients with Previously Treated Locally Advanced or Metastatic Breast Cancer. <i>Oncologist</i> , 2017, 22, 245-254.	1.9	21
129	Combination antiretroviral therapy accelerates immune recovery in patients with HIV-related lymphoma treated with EPOCH: a comparison within one prospective trial AMC034. <i>Leukemia and Lymphoma</i> , 2018, 59, 1851-1860.	0.6	21
130	Defining the Clinical Utility of Gene Expression Assays in Breast Cancer: The Intersection of Science and Art in Clinical Decision Making. <i>Journal of Clinical Oncology</i> , 2010, 28, 1625-1627.	0.8	20
131	Relationship between Quantitative <i>GRB7</i> RNA Expression and Recurrence after Adjuvant Anthracycline Chemotherapy in Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 7194-7203.	3.2	20
132	A phase II trial of capecitabine in combination with the farnesyltransferase inhibitor tipifarnib in patients with anthracycline-treated and taxane-resistant metastatic breast cancer: an Eastern Cooperative Oncology Group Study (E1103). <i>Breast Cancer Research and Treatment</i> , 2012, 134, 345-352.	1.1	20
133	Phase II study of the farnesyl transferase inhibitor tipifarnib plus sequential weekly paclitaxel and doxorubicin cyclophosphamide in HER2/neu-negative inflammatory carcinoma and non-inflammatory estrogen receptor-positive breast carcinoma. <i>Breast Cancer Research and Treatment</i> , 2013, 141, 429-435.	1.1	20
134	Breast cancer patients' insurance status and residence zip code correlate with early discontinuation of endocrine therapy: An analysis of the ECOG-ACRIN TAILORx trial. <i>Cancer</i> , 2021, 127, 2545-2552.	2.0	20
135	Vismodegib (V), a hedgehog (HH) pathway inhibitor, combined with FOLFOX for first-line therapy of patients (pts) with advanced gastric and gastroesophageal junction (GEJ) carcinoma: A New York Cancer Consortium led phase II randomized study.. <i>Journal of Clinical Oncology</i> , 2013, 31, 4011-4011.	0.8	20
136	HIV-associated lymphoma: the evidence for treating aggressively but with caution. <i>Current Opinion in Oncology</i> , 2007, 19, 458-463.	1.1	19
137	Mitotic counts in breast cancer after neoadjuvant systemic chemotherapy and development of metastatic disease. <i>Breast Cancer Research and Treatment</i> , 2013, 138, 91-97.	1.1	19
138	Central nervous system involvement in AIDS-related lymphomas. <i>British Journal of Haematology</i> , 2016, 173, 857-866.	1.2	19
139	A 21-Gene Expression Assay in Breast Cancer. <i>New England Journal of Medicine</i> , 2016, 374, 1385-1387.	13.9	19
140	Phase I and pharmacokinetic study of veliparib, a PARP inhibitor, and pegylated liposomal doxorubicin (PLD) in recurrent gynecologic cancer and triple negative breast cancer with long-term follow-up. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 741-751.	1.1	19
141	Complete remission in refractory anaplastic adult wilms' tumor treated with cisplatin and etoposide. <i>Cancer</i> , 1991, 67, 956-959.	2.0	18
142	Human immunodeficiency virus associated lymphoma. <i>Current Opinion in Oncology</i> , 2003, 15, 372-378.	1.1	18
143	A Phase I Trial of Oblimersen Sodium in Combination With Cisplatin and 5-Fluorouracil in Patients With Advanced Esophageal, Gastroesophageal Junction, and Gastric Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2010, 33, 61-65.	0.6	17
144	Enriched transcription factor signatures in triple negative breast cancer indicates possible targeted therapies with existing drugs. <i>Meta Gene</i> , 2015, 4, 129-141.	0.3	17

#	ARTICLE	IF	CITATIONS
145	A Phase I/II study of suberoylanilide hydroxamic acid (SAHA) in combination with trastuzumab (Herceptin) in patients with advanced metastatic and/or local chest wall recurrent HER2-amplified breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1104). <i>Breast Cancer Research and Treatment</i> , 2017, 165, 375-382.	1.1	17
146	Phase I Trial of Veliparib, a Poly ADP Ribose Polymerase Inhibitor, Plus Metronomic Cyclophosphamide in Metastatic HER2-negative Breast Cancer. <i>Clinical Breast Cancer</i> , 2018, 18, e135-e142.	1.1	17
147	Black race and distant recurrence after neoadjuvant or adjuvant chemotherapy in breast cancer. <i>Clinical and Experimental Metastasis</i> , 2018, 35, 613-623.	1.7	17
148	Preoperative Breast MRI for Newly Diagnosed Ductal Carcinoma in Situ: Imaging Features and Performance in a Multicenter Setting (ECOG-ACRIN E4112 Trial). <i>Radiology</i> , 2021, 301, 66-77.	3.6	17
149	Phase II trials of cetuximab (CX) plus cisplatin (CDDP), 5-fluorouracil (5-FU) and radiation (RT) in immunocompetent (ECOG 3205) and HIV-positive (AMC045) patients with squamous cell carcinoma of the anal canal (SCAC): Safety and preliminary efficacy results.. <i>Journal of Clinical Oncology</i> , 2012, 30, 4030-4030.	0.8	17
150	Efficacy of the combination of ABT-888 (veliparib) and carboplatin in patients with BRCA-associated breast cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, 1024-1024.	0.8	17
151	TOP2A RNA expression and recurrence in estrogen receptor-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012, 134, 751-757.	1.1	16
152	Risk of Recurrence and Mortality in a Multi-Ethnic Breast Cancer Population. <i>Journal of Racial and Ethnic Health Disparities</i> , 2017, 4, 1181-1188.	1.8	16
153	Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical Considerations. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz050.	1.4	15
154	Phase I/II trial of ruxolitinib in combination with trastuzumab in metastatic HER2 positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 189, 177-185.	1.1	15
155	Inflammatory cytokines and distant recurrence in HER2-negative early breast cancer. <i>Npj Breast Cancer</i> , 2022, 8, 16.	2.3	15
156	Cerebral infection complicating systemic aspergillosis in acute leukemia: clinical and radiographic presentation. <i>Journal of Neuro-Oncology</i> , 1992, 13, 91-100.	1.4	14
157	Comparative clinical benefits of systemic adjuvant therapy for paradigm solid tumors. <i>Cancer Treatment Reviews</i> , 2013, 39, 27-43.	3.4	14
158	Increased Expression of Tumor Proliferation Genes in Hispanic Women with Early-Stage Breast Cancer. <i>Cancer Investigation</i> , 2014, 32, 439-444.	0.6	14
159	Simulation Modeling of Cancer Clinical Trials: Application to Omitting Radiotherapy in Low-risk Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2018, 110, 1360-1369.	3.0	14
160	Clinical Trials for Treatment and Prevention of HIV-Associated Malignancies in Sub-Saharan Africa: Building Capacity and Overcoming Barriers. <i>JCO Global Oncology</i> , 2020, 6, 1134-1146.	0.8	14
161	Phase II trial of single agent PARP inhibitor ABT-888 (veliparib [vel]) followed by postprogression therapy of vel with carboplatin (carb) in patients (pts) with stage BRCA-associated metastatic breast cancer (MBC): California Cancer Consortium trial PHII-96.. <i>Journal of Clinical Oncology</i> , 2014, 32, 1021-1021.	0.8	14
162	Rhabdomyolysis: An unusual complication of cytotoxic chemotherapy. <i>Medical Oncology</i> , 1995, 12, 219-222.	1.2	13

#	ARTICLE	IF	CITATIONS
163	Predictive Value of Cytokines and Immune Activation Biomarkers in AIDS-Related Non-Hodgkin Lymphoma Treated with Rituximab plus Infusional EPOCH (AMC-034 trial). <i>Clinical Cancer Research</i> , 2016, 22, 328-336.	3.2	13
164	Efficacy and Safety of Ribociclib With Letrozole in US Patients Enrolled in the MONALEESA-2 Study. <i>Clinical Breast Cancer</i> , 2019, 19, 268-277.e1.	1.1	13
165	Association of Modifiable Risk Factors With Early Discontinuation of Adjuvant Endocrine Therapy. <i>JAMA Oncology</i> , 2021, 7, 1196.	3.4	13
166	Tenascin pattern of expression and established prognostic factors in invasive breast carcinoma. , 1998, 68, 107-112.		12
167	Clinical application of molecular profiling in breast cancer. <i>Future Oncology</i> , 2005, 1, 485-496.	1.1	12
168	The TAILORx trial: individualized options for treatment. <i>Community Oncology</i> , 2006, 3, 494-496.	0.2	12
169	Phase II trial of bortezomib alone or in combination with irinotecan in patients with adenocarcinoma of the gastroesophageal junction or stomach. <i>Investigational New Drugs</i> , 2014, 32, 542-548.	1.2	12
170	Lymphovascular invasion, race, and the 21-gene recurrence score in early estrogen receptor-positive breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 20.	2.3	12
171	Deconstructing Racial and Ethnic Disparities in Breast Cancer. <i>JAMA Oncology</i> , 2021, 7, 355.	3.4	12
172	Neoadjuvant clinical trials provide a window of opportunity for cancer drug discovery. <i>Nature Medicine</i> , 2022, 28, 626-629.	15.2	12
173	Carbohydrate restriction in patients with advanced cancer: a protocol to assess safety and feasibility with an accompanying hypothesis. <i>Community Oncology</i> , 2008, 5, 22-26.	0.2	11
174	Maintenance of Clinical Efficacy After Dose Reduction of Ixabepilone Plus Capecitabine in Patients With Anthracycline- and Taxane-Resistant Metastatic Breast Cancer: A Retrospective Analysis of Pooled Data From 2 Phase III Randomized Clinical Trials. <i>Clinical Breast Cancer</i> , 2012, 12, 240-246.	1.1	11
175	Do Community-Based Patient Assistance Programs Affect the Treatment and Well-Being of Patients With Breast Cancer?. <i>Journal of Oncology Practice</i> , 2014, 10, 48-54.	2.5	11
176	High Expression of FGD3, a Putative Regulator of Cell Morphology and Motility, Is Prognostic of Favorable Outcome in Multiple Cancers. <i>JCO Precision Oncology</i> , 2017, 1, 1-13.	1.5	11
177	Safety and Preliminary Efficacy of Vorinostat WithÂR-EPOCH in High-risk HIV-associated Non-Hodgkin's Lymphoma (AMC-075). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 180-190.e2.	0.2	11
178	Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 2: Approaches to Predict and Identify Late Recurrence, Research Directions. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz049.	1.4	11
179	Surveillance After Treatment of Localized Breast Cancer: Time for Reappraisal?. <i>Journal of the National Cancer Institute</i> , 2019, 111, 339-341.	3.0	11
180	Phase I Study of Veliparib on an Intermittent and Continuous Schedule in Combination with Carboplatin in Metastatic Breast Cancer: A Safety and [18F]-Fluorothymidine Positron Emission Tomography Biomarker Study. <i>Oncologist</i> , 2020, 25, e1158-e1169.	1.9	11

#	ARTICLE	IF	CITATIONS
181	TAILORx: Phase III trial of chemoendocrine therapy versus endocrine therapy alone in hormone receptor-positive, HER2-negative, node-negative breast cancer and an intermediate prognosis 21-gene recurrence score.. <i>Journal of Clinical Oncology</i> , 2018, 36, LBA1-LBA1.	0.8	11
182	The 21-gene recurrence score in early non-ductal breast cancer: a National Cancer Database analysis. <i>Npj Breast Cancer</i> , 2022, 8, 4.	2.3	11
183	Racial disparity in distant recurrence-free survival in patients with localized breast cancer: A pooled analysis of National Surgical Adjuvant Breast and Bowel Project trials. <i>Cancer</i> , 2022, 128, 2728-2735.	2.0	11
184	Adjuvant Therapy in Stage I Carcinoma of the Breast: The Influence of Multigene Analyses and Molecular Phenotyping. <i>Breast Journal</i> , 2012, 18, 303-311.	0.4	10
185	Variable Problems in Lymphomas. <i>Journal of Clinical Oncology</i> , 2005, 23, 8116-8117.	0.8	9
186	Safety and efficacy of an oncolytic viral strategy using bortezomib with ICE/R in relapsed/refractory HIV-positive lymphomas. <i>Blood Advances</i> , 2018, 2, 3618-3626.	2.5	9
187	Efficacy of the PARP inhibitor (PI) ABT-888 (veliparib [vel]) either with carboplatin (carb) or as a single agent followed by post-progression therapy in combination with carb in patients (pts) with <i>BRCA1</i> or <i>BRCA2</i> ( <i>BRCA</i> )-associated metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 520-520.	0.8	9
188	Plasma Matrix Metalloproteinases 7 and 9 in Patients with Metastatic Breast Cancer Treated with Marimastat or Placebo: Eastern Cooperative Oncology Group Trial E2196. <i>Clinical Breast Cancer</i> , 2006, 6, 525-529.	1.1	8
189	Cetuximab is Associated With Excessive Toxicity When Combined With Bevacizumab Plus mFOLFOX6 in Metastatic Colorectal Carcinoma. <i>Clinical Colorectal Cancer</i> , 2010, 9, 290-296.	1.0	8
190	Chronic Thalidomide and Chemoembolization for Hepatocellular Carcinoma. <i>Oncologist</i> , 2014, 19, 1229-1230.	1.9	8
191	Macrocytosis and dysplastic anemia is associated with the cyclin-dependent kinase 4/6 inhibitor palbociclib in metastatic breast cancer. <i>Haematologica</i> , 2018, 103, e98-e102.	1.7	8
192	Response-adapted therapy with infusional EPOCH chemotherapy plus rituximab in HIV-associated, B-cell non-Hodgkin's lymphoma. <i>Haematologica</i> , 2021, 106, 730-735.	1.7	8
193	Efficacy and safety of ixabepilone plus capecitabine in elderly patients with anthracycline- and taxane-pretreated metastatic breast cancer. <i>Journal of Geriatric Oncology</i> , 2013, 4, 346-352.	0.5	7
194	Validation of an Automated Quantitative Digital Pathology Approach for Scoring TMEM: A Prognostic Biomarker for Metastasis. <i>Cancers</i> , 2020, 12, 846.	1.7	7
195	Expanding Criteria for Prognostic Stage IA in Hormone Receptor-Positive Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1744-1750.	3.0	7
196	Development and Validation of a Simulation Model-Based Clinical Decision Tool: Identifying Patients Where 21-Gene Recurrence Score Testing May Change Decisions. <i>Journal of Clinical Oncology</i> , 2021, 39, 2893-2902.	0.8	7
197	Translating Genomic Research into Clinical Practice: Promise and Pitfalls. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, 33, 15-23.	1.8	7
198	ABT-888 (veliparib) in combination with carboplatin in patients with stage IV BRCA-associated breast cancer. A California Cancer Consortium Trial.. <i>Journal of Clinical Oncology</i> , 2012, 30, 1010-1010.	0.8	7

#	ARTICLE	IF	CITATIONS
199	Disseminated aspergillosis after fungemia in a patient with extragonadal germ cell tumor undergoing autologous bone marrow transplantation. <i>Cancer</i> , 1991, 68, 1842-1844.	2.0	6
200	A Phase I Trial of Gemcitabine Administered as a 96-h Continuous Intravenous Infusion in Patients with Advanced Carcinoma and Lymphoma. <i>Medical Oncology</i> , 2006, 23, 369-376.	1.2	6
201	Reply to K. Dunleavy et al. <i>Journal of Clinical Oncology</i> , 2010, 28, e261-e262.	0.8	6
202	Paradigms and Controversies in the Treatment of HIV-Related Burkitt Lymphoma. <i>Advances in Hematology</i> , 2012, 2012, 1-8.	0.6	6
203	Patient-Reported Testing Burden of Breast Magnetic Resonance Imaging Among Women With Ductal Carcinoma In Situ. <i>JAMA Network Open</i> , 2021, 4, e2129697.	2.8	6
204	How Do I Treat Inflammatory Breast Cancer?. <i>Current Treatment Options in Oncology</i> , 2013, 14, 66-74.	1.3	5
205	New agents for the management of resistant metastatic breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 1815-1831.	0.9	5
206	TAILORx: Questions Answered, Lessons Learned, and Remaining Knowledge Gaps. <i>Journal of Clinical Oncology</i> , 2019, 37, 1841-1842.	0.8	5
207	Randomized Phase II Trial of Capecitabine and Lapatinib with or without IMC-A12 (Cituxumumab) in Patients with HER2-Positive Advanced Breast Cancer Previously Treated with Trastuzumab and Chemotherapy: NCCTG N0733 (Alliance). <i>Breast Cancer Research and Treatment</i> , 2021, 188, 477-487.	1.1	5
208	Phase II trial of echinomycin in patients with advanced or recurrent colorectal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 1994, 34, 266-269.	1.1	5
209	10-year update of E2197: Phase III doxorubicin/docetaxel (AT) versus doxorubicin/cyclophosphamide (AC) adjuvant treatment of LN+ and high-risk LN- breast cancer and the comparison of the prognostic utility of the 21-gene recurrence score (RS) with clinicopathologic features.. <i>Journal of Clinical Oncology</i> , 2012, 30, 1021-1021.	0.8	5
210	First-line ribociclib plus letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): MONALEESA-2 safety results.. <i>Journal of Clinical Oncology</i> , 2017, 35, 1047-1047.	0.8	5
211	AMC 095 (AIDS Malignancy Consortium): A phase I study of ipilimumab (IPI) and nivolumab (NIVO) in advanced HIV associated solid tumors (ST) with expansion cohorts in HIV associated solid tumors and classical Hodgkin lymphoma (cHL).. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS2597-TPS2597.	0.8	5
212	Neoadjuvant trastuzumab (H), pertuzumab (P), and chemotherapy versus trastuzumab emtansine (T-DM1) and P in human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC): Final outcome results from the phase III KRISTINE study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 500-500.	0.8	5
213	Farnesyl Transferase Inhibitors. <i>Cancer Investigation</i> , 2008, 26, 653-661.	0.6	4
214	Evaluation of serum Amphiregulin levels in breast cancer patients and cancer-free controls. <i>Experimental Hematology and Oncology</i> , 2013, 2, 25.	2.0	4
215	Prognostic gene expression assays in breast cancer: are two better than one?. <i>Npj Breast Cancer</i> , 2018, 4, 11.	2.3	4
216	The clinical utility of gene expression assays in breast cancer patients with $\geq 3$ involved lymph nodes. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110384.	1.4	4

#	ARTICLE	IF	CITATIONS
217	Immune Activation and Microbial Translocation as Prognostic Biomarkers for AIDS-Related Non-Hodgkin Lymphoma in the AMC-034 Study. <i>Clinical Cancer Research</i> , 2021, 27, 4642-4651.	3.2	4
218	Phase II trials of cetuximab plus combined modality therapy (CMT) in squamous cell carcinoma of the anal canal (SCCAC) with and without human immunodeficiency virus (HIV) infection.. <i>Journal of Clinical Oncology</i> , 2016, 34, 3522-3522.	0.8	4
219	A randomized phase II trial of fulvestrant with or without ribociclib after progression on aromatase inhibition plus cyclin-dependent kinase 4/6 inhibition in patients with unresectable or metastatic hormone receptor positive, HER2 negative breast cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS1112-TPS1112.	0.8	4
220	Translating Genomic Research into Clinical Practice: Promise and Pitfalls. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, , 15-23.	1.8	4
221	The AKT inhibitor triciribine in combination with paclitaxel has order-specific efficacy against Zfp217-induced breast cancer chemoresistance. <i>Oncotarget</i> , 2017, 8, 108534-108547.	0.8	4
222	Phase I Trial of Infusional Cyclophosphamide, Doxorubicin, and Etoposide plus Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in Non-Hodgkin's Lymphoma. <i>Medical Oncology</i> , 2005, 22, 257-268.	1.2	3
223	Targeting Epigenetic Modifications for the Treatment and Prevention of Breast Cancer. <i>Current Breast Cancer Reports</i> , 2010, 2, 198-207.	0.5	3
224	Recommendations for research priorities in breast cancer by the Coalition of Cancer Cooperative Groups Scientific Leadership Council: systemic therapy and therapeutic individualization. <i>Breast Cancer Research and Treatment</i> , 2010, 119, 511-527.	1.1	3
225	Neoadjuvant Systemic Therapy for Breast Cancer. <i>JAMA Oncology</i> , 2018, 4, 293.	3.4	3
226	Perspectives on PARP inhibitors as pharmacotherapeutic strategies for breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1-23.	0.9	3
227	Reply to T. Shimoi et al and Y. Shimanuki et al. <i>Journal of Clinical Oncology</i> , 2021, 39, JCO.21.01905.	0.8	3
228	Genomic and Pathway Connectivity Analyses Identify Novel Strategies to Overcome mTOR Inhibitor Resistance In DLBCL. <i>Blood</i> , 2010, 116, 436-436.	0.6	3
229	A multicenter phase II study of bevacizumab (B) and temsirolimus (T) in women with recurrent epithelial ovarian cancer (OC): A study of the Mayo, Chicago, California, New York, Southeast, and Princess Margaret Phase II Consortia.. <i>Journal of Clinical Oncology</i> , 2013, 31, 5517-5517.	0.8	3
230	Presurgical evaluation of the AKT inhibitor MK-2206 in patients with operable invasive breast cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 2613-2613.	0.8	3
231	Refined estimates of local recurrence risks and the impact of the DCIS score adjusting for clinico-pathological features: Meta-analysis of E5194 and Ontario DCIS cohort studies.. <i>Journal of Clinical Oncology</i> , 2017, 35, 528-528.	0.8	3
232	A phase I/II dose escalation and expansion study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in combination with fulvestrant in subjects with ER+ breast cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS1114-TPS1114.	0.8	3
233	Fatigue and endocrine symptoms among women with early breast cancer randomized to endocrine versus chemoendocrine therapy: Results from the TAILORx patient-reported outcomes substudy. <i>Cancer</i> , 2021, , .	2.0	3
234	Long-Term Follow-up of Rituximab and Infusional Cyclophosphamide, Doxorubicin, and Etoposide (CDE) In Combination with HAART In HIV-Related Non-Hodgkin's Lymphomas (NHL). <i>Blood</i> , 2010, 116, 5072-5072.	0.6	3

#	ARTICLE	IF	CITATIONS
235	Tolerability of bevacizumab and chemotherapy in a phase 3 clinical trial with human epidermal growth factor receptor 2-negative breast cancer: A trajectory analysis of adverse events. <i>Cancer</i> , 2021, 127, 4546-4556.	2.0	3
236	Association Between Surgery Preference and Receipt in Ductal Carcinoma In Situ After Breast Magnetic Resonance Imaging. <i>JAMA Network Open</i> , 2022, 5, e2210331.	2.8	3
237	Reply to B. UlaÅ Kahya et al and A. Soran et al. <i>Journal of Clinical Oncology</i> , 0, , .	0.8	3
238	Recommendations for research priorities in breast cancer by the coalition of cancer cooperative groups scientific leadership council: imaging and local therapy. <i>Breast Cancer Research and Treatment</i> , 2010, 120, 273-284.	1.1	2
239	Learning from big data: are we undertreating older women with high-risk breast cancer?. <i>Npj Breast Cancer</i> , 2016, 2, 16019.	2.3	2
240	Simulation Modeling to Extend Clinical Trials of Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Early Breast Cancer. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz062.	1.4	2
241	Tenascin pattern of expression and established prognostic factors in invasive breast carcinoma. , 1998, 68, 107.		2
242	AMC-053: Pilot Study of an Oncolytic Viral Strategy Using Bortezomib with ICE +/- Rituximab for Relapsed/Refractory HIV+ Lymphomas. <i>Blood</i> , 2016, 128, 786-786.	0.6	2
243	Genome wide association study for anthracycline-induced congestive heart failure.. <i>Journal of Clinical Oncology</i> , 2016, 34, 1017-1017.	0.8	2
244	Cobimetinib (C) + paclitaxel (P) as first-line treatment in patients (pts) with advanced triple-negative breast cancer (TNBC): Updated results and biomarker data from the phase 2 COLET study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 1074-1074.	0.8	2
245	A phase II prospective trial correlating progression-free survival (PFS) with CYP2D6 activity in patients with metastatic breast cancer treated with tamoxifen: ECOG-ACRIN E3108.. <i>Journal of Clinical Oncology</i> , 2016, 34, 546-546.	0.8	2
246	AIDS malignancy consortium (AMC) 095: A phase I study of ipilimumab (IPI) and nivolumab (NIVO) in advanced HIV-associated solid tumors (ST) with expansion cohorts in HIV-associated solid tumors and classical Hodgkin lymphoma (cHL).. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS44-TPS44.	0.8	2
247	Safety and Tolerability of Carboplatin and Paclitaxel in Cancer Patients with HIV (AMC-078), an AIDS Malignancy Consortium (AMC) Study. <i>Oncologist</i> , 2022, 27, 623-e624.	1.9	2
248	Plasma extracellular vesicles bearing PD-L1, CD40, CD40L or TNF-RII are significantly reduced after treatment of AIDS-NHL. <i>Scientific Reports</i> , 2022, 12, .	1.6	2
249	Immunological Therapy of Breast Cancer. <i>BioDrugs</i> , 1994, 1, 135-147.	0.7	1
250	Taxane-Based Therapy for Breast Cancer: Combination or Sequential Therapy?. <i>Cancer Investigation</i> , 2000, 18, 498-500.	0.6	1
251	Reply to J.M. Guinebretiere and L. Arnould et al. <i>Journal of Clinical Oncology</i> , 2009, 27, 2734-2735.	0.8	1
252	Is there a role for ovarian function suppression in operable breast cancer?. <i>Breast Cancer Research and Treatment</i> , 2010, 123, 311-313.	1.1	1

#	ARTICLE	IF	CITATIONS
253	Reply to T. Grenader et al. Journal of Clinical Oncology, 2010, 28, e195-e196.	0.8	1
254	Techniques and Thresholds for Quantifying Circulating Tumor Cells in Breast Cancer—In Reply. JAMA Oncology, 2019, 5, 574.	3.4	1
255	RE: Advanced Breast Cancer Definitions by Staging System Examined in the Breast Cancer Surveillance Consortium. Journal of the National Cancer Institute, 2021, 113, 938-939.	3.0	1
256	Patterns of central nervous system recurrence in patients with systemic human immunodeficiency virus-associated non-Hodgkin lymphoma. , 1999, 86, 1840.		1
257	A pooled analysis of 1,144 patients with HIV-associated lymphoma: Assessment of lymphoma-, HIV-, and treatment-specific factors on clinical outcomes.. Journal of Clinical Oncology, 2012, 30, 8005-8005.	0.8	1
258	Prospective study of magnetic resonance imaging (MRI) and multiparameter gene expression assay in ductal carcinoma in situ (DCIS): A trial of the ECOG-ACRIN Cancer Research Group (E4112).. Journal of Clinical Oncology, 2017, 35, 534-534.	0.8	1
259	AMC075: A randomized phase II trial of vorinostat with R-EPOCH in aggressive HIV-related NHL.. Journal of Clinical Oncology, 2018, 36, 7573-7573.	0.8	1
260	Molecular markers of risk of subsequent invasive breast cancer in women with ductal carcinoma in situ: protocol for a population-based cohort study. BMJ Open, 2021, 11, e053397.	0.8	1
261	Phase I-II study of the histone deacetylase inhibitor vorinostat plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in locally advanced breast cancer.. Journal of Clinical Oncology, 2014, 32, 598-598.	0.8	1
262	Recurrence score and clinicopathologic characteristics of TAILORx participants by race and ethnicity.. Journal of Clinical Oncology, 2014, 32, 36-36.	0.8	1
263	Phase Ib study of rebastinib plus antitubulin therapy with paclitaxel or eribulin in patients with metastatic breast cancer (MBC).. Journal of Clinical Oncology, 2017, 35, TPS2611-TPS2611.	0.8	1
264	Breast cancer patients who are obese at diagnosis: alea iacta est? or "is the die cast"?. Oncology, 2011, 25, 1002, 1004, 1007.	0.4	1
265	Abstract P4-10-02: Patient-reported outcomes in EA1131: A randomized phase III trial of platinum vs. capecitabine in patients with residual triple-negative breast cancer after neoadjuvant chemotherapy. Cancer Research, 2022, 82, P4-10-02-P4-10-02.	0.4	1
266	Reply to T.J. Smith et al. Journal of Clinical Oncology, 2010, 28, e129-e130.	0.8	0
267	Taxane chemotherapy treatment for metastatic breast cancer. Breast Cancer Management, 2013, 2, 507-517.	0.2	0
268	Reply to C. Shah et al. Journal of Clinical Oncology, 2016, 34, 1824-1825.	0.8	0
269	In Regard to Bruner et al. International Journal of Radiation Oncology Biology Physics, 2016, 94, 1220-1221.	0.4	0
270	Tailoring Adjuvant Therapy for Breast Cancer in the Elderly: Room for Improvement. Breast Journal, 2017, 23, 253-255.	0.4	0

#	ARTICLE	IF	CITATIONS
271	Applying the Hippocratic Oath in breast cancer-The case for promoting prevention. Breast Journal, 2019, 25, 187-189.	0.4	0
272	Use of the 21-Gene Recurrence Score to Predict Clinical Outcomes in Early Breast Cancer—Reply. JAMA Oncology, 2020, 6, 586.	3.4	0
273	Reply to K. Ando et al. Journal of Clinical Oncology, 2021, 39, 1947-1948.	0.8	0
274	Long-Term Follow-up of Rituximab and Infusional Cyclophosphamide, Doxorubicin, and Etoposide (cde) in Combination with HAART in HIV-Related Non-Hodgkin's Lymphomas (NHL).. Blood, 2008, 112, 1467-1467.	0.6	0
275	Targeting EGFR in HPV-Associated Cancer. , 2010, , 211-234.		0
276	Comparison of the incidence of peripheral neuropathy (PN) with eribulin versus ixabepilone (IXA) in metastatic breast cancer (MBC) patients: A randomized phase II study.. Journal of Clinical Oncology, 2012, 30, 121-121.	0.8	0
277	Biomarker prediction of chemotherapy-related amenorrhea.. Journal of Clinical Oncology, 2013, 31, 9508-9508.	0.8	0
278	A phase III study of tipifarnib plus weekly paclitaxel (P) followed by dose-dense doxorubicin/cyclophosphamide (AC) in stage IIb-IIIc breast cancer (BC).. Journal of Clinical Oncology, 2013, 31, 1118-1118.	0.8	0
279	CNS involvement in patients with AIDS-related lymphomas.. Journal of Clinical Oncology, 2014, 32, 8570-8570.	0.8	0
280	Recurrence score and clinicopathologic characteristics of TAILORx participants by race and ethnicity.. Journal of Clinical Oncology, 2015, 33, 533-533.	0.8	0
281	Tumor Infiltrating Lymphocytes as a Prognostic and Predictive Biomarker in Breast Cancer. , 2016, , 167-186.		0
282	The Tumor Microenvironment as a Metastasis Biomarker in Breast Cancer. , 2016, , 153-165.		0
283	Suppression of poly-ADP ribose (PAR) levels in PBMCs by veliparib (vel) as a pharmacodynamic (PD) marker associated with survival among women with BRCA1- or BRCA2- (BRCA)-associated metastatic breast cancer (MBC).. Journal of Clinical Oncology, 2016, 34, 2549-2549.	0.8	0
284	Association of Charcot-Marie-Tooth gene, SBF2, with taxane-induced peripheral neuropathy in African Americans.. Journal of Clinical Oncology, 2016, 34, 1026-1026.	0.8	0
285	Long-term outcomes in women with low-risk hormone-sensitive early-stage breast cancer.. Journal of Clinical Oncology, 2018, 36, e12583-e12583.	0.8	0
286	Breast Cancer Management in the TAILORx Era: Less is More. NAM Perspectives, 0, , .	1.3	0
287	Simulation modeling of the effects of adjuvant chemotherapy in early-stage breast cancer.. Journal of Clinical Oncology, 2019, 37, 526-526.	0.8	0
288	Systemic therapy for triple-negative breast cancer: A changing landscape. Critical Reviews in Oncology/Hematology, 2022, 171, 103608.	2.0	0

#	ARTICLE	IF	CITATIONS
289	Abstract PD9-01: Expanding downstaging criteria in AJCC pathologic prognostic staging using OncotypeDx Recurrence Score® assay in T1-2N0 hormone-receptor positive patients enrolled in the TAILORx trial. <i>Cancer Research</i> , 2022, 82, PD9-01-PD9-01.	0.4	0
290	Correlation of Ki67 working group prognostic risk categories with oncotype DX recurrence score (RS) in early breast cancer (EBC).. <i>Journal of Clinical Oncology</i> , 2022, 40, 553-553.	0.8	0